Biomarkers of response to NAE inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10953013
APP PUB NO 20170105995A1
SERIAL NO

15173393

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
TAKEDA PHARMACEUTICAL COMPANY LIMITEDOSAKA-SHI OSAKA 541-0045

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Benes, Cyril H Brookline, US 2 6
Blakemore, Stephen J Littleton, US 12 22
Blank, Jonathan L Westborough, US 2 6
Lightcap, Eric S Natick, US 7 67
Mulligan, George J Lexington, US 12 92
Schu, Matthew C Somerville, US 3 11
Settleman, Jeffrey E Mill Valley, US 14 777
Smith, Peter G Arlington, US 32 685

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 23, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 23, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00